Cargando…

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial

Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To e...

Descripción completa

Detalles Bibliográficos
Autores principales: Amat-Bou, Montse, Garcia-Ribera, Sonika, Climent, Eric, Piquer-Garcia, Irene, Corripio, Raquel, Sanchez-Infantes, David, Villalta, Laia, Elias, Maria, Jiménez-Chillarón, Josep C., Chenoll, Empar, Ramón, Daniel, Ibañez, Lourdes, Ramon-Krauel, Marta, Lerin, Carles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650793/
https://www.ncbi.nlm.nih.gov/pubmed/33066107
http://dx.doi.org/10.3390/nu12103123
_version_ 1783607555581280256
author Amat-Bou, Montse
Garcia-Ribera, Sonika
Climent, Eric
Piquer-Garcia, Irene
Corripio, Raquel
Sanchez-Infantes, David
Villalta, Laia
Elias, Maria
Jiménez-Chillarón, Josep C.
Chenoll, Empar
Ramón, Daniel
Ibañez, Lourdes
Ramon-Krauel, Marta
Lerin, Carles
author_facet Amat-Bou, Montse
Garcia-Ribera, Sonika
Climent, Eric
Piquer-Garcia, Irene
Corripio, Raquel
Sanchez-Infantes, David
Villalta, Laia
Elias, Maria
Jiménez-Chillarón, Josep C.
Chenoll, Empar
Ramón, Daniel
Ibañez, Lourdes
Ramon-Krauel, Marta
Lerin, Carles
author_sort Amat-Bou, Montse
collection PubMed
description Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1′s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo–BPL1 (n = 19) or BPL1–placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480).
format Online
Article
Text
id pubmed-7650793
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76507932020-11-10 Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial Amat-Bou, Montse Garcia-Ribera, Sonika Climent, Eric Piquer-Garcia, Irene Corripio, Raquel Sanchez-Infantes, David Villalta, Laia Elias, Maria Jiménez-Chillarón, Josep C. Chenoll, Empar Ramón, Daniel Ibañez, Lourdes Ramon-Krauel, Marta Lerin, Carles Nutrients Article Prader–Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1′s effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo–BPL1 (n = 19) or BPL1–placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480). MDPI 2020-10-13 /pmc/articles/PMC7650793/ /pubmed/33066107 http://dx.doi.org/10.3390/nu12103123 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amat-Bou, Montse
Garcia-Ribera, Sonika
Climent, Eric
Piquer-Garcia, Irene
Corripio, Raquel
Sanchez-Infantes, David
Villalta, Laia
Elias, Maria
Jiménez-Chillarón, Josep C.
Chenoll, Empar
Ramón, Daniel
Ibañez, Lourdes
Ramon-Krauel, Marta
Lerin, Carles
Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title_full Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title_fullStr Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title_full_unstemmed Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title_short Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader–Willi Syndrome: A Randomized Crossover Trial
title_sort effects of bifidobacterium animalis subsp. lactis (bpl1) supplementation in children and adolescents with prader–willi syndrome: a randomized crossover trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650793/
https://www.ncbi.nlm.nih.gov/pubmed/33066107
http://dx.doi.org/10.3390/nu12103123
work_keys_str_mv AT amatboumontse effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT garciariberasonika effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT climenteric effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT piquergarciairene effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT corripioraquel effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT sanchezinfantesdavid effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT villaltalaia effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT eliasmaria effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT jimenezchillaronjosepc effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT chenollempar effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT ramondaniel effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT ibanezlourdes effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT ramonkrauelmarta effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial
AT lerincarles effectsofbifidobacteriumanimalissubsplactisbpl1supplementationinchildrenandadolescentswithpraderwillisyndromearandomizedcrossovertrial